Abstract: This invention relates to the novel compounds 3',5,7-trihydroxy-4',6-dimethoxy-isoflavone, 3'5,7-trihydroxy-4',8-dimethoxy-isoflavone and 3',7-dihydroxy-4',6,8-trimethoxy-isoflavone which are powerful inhibitors of catechol-O-methyl transferase (COMT) and to their production by fermentation of Actinomyces roseolus.
Type:
Grant
Filed:
July 23, 1974
Date of Patent:
August 10, 1976
Assignee:
Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai
Abstract: Compounds having the general formula ##SPC1##(the meanings of R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are indicated hereinafter) and the pharmaceutically acceptable salts and esters thereof exhibit strong activities in inhibiting histidine decarboxylase and xanthine oxidase.
Type:
Grant
Filed:
April 17, 1974
Date of Patent:
August 3, 1976
Assignee:
Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai
Abstract: This invention relates to a process for the preparation of coformycin, 3-(.beta.-D-ribofuranosyl)-6,7,8-trihydroimidazo[4,5-d][1,3]diazepin-8(R)- ol, through a synthetic route from a new derivative of 9-.beta.-D-ribofuranosyl-purine and other synthetic intermediates involved in the process and their preparation.
Type:
Grant
Filed:
October 24, 1974
Date of Patent:
May 25, 1976
Assignee:
Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai
Abstract: Calcium .alpha.-p-chlorophenoxyisobutyrate, particularly as its novel monohydrate, when combined with about one to two parts by weight of calcium carbonate in oral dosage form for use in mammals, and especially man, provides a safe and effective composition for reducing elevated blood levels of cholesterol, triglycerides and/or low density lipoproteins and/or increasing fibrinolytic activity and/or decreasing platelet aggregation. A preferred embodiment is a capsule containing 500 mgm. calcium carbonate and 250 or 500 mgm. crystalline calcium .alpha.-p-chlorophenoxyisobutyrate monohydrate having the empirical formula C.sub.10 H.sub.10 ClO.sub.3 Ca.sub.1/2.H.sub.2 O.
Type:
Grant
Filed:
June 15, 1973
Date of Patent:
April 20, 1976
Assignee:
Bristol-Myers Company
Inventors:
John Carl Godfrey, John Edwin MacNintch, Joseph Rubinfeld
Abstract: The title compounds, which can also be called oxapenicillins G and V, are produced by chemical synthesis and then, if desired, are deacylated.
Abstract: The title compound is produced by chemical synthesis and, if desired, converted as by N-phenylacetylation to a new .beta.-lactam antibiotic such as oxapenicillin G.
Abstract: 7-[.alpha.-(2-Aminomethyl-1-cyclohexyl)-acetamido]-3-heterocyclic thiomethyl-3-cephem-4-carboxylic acids, and their nontoxic, pharmaceutically acceptable salts and their Schiff bases, as made by reaction of salicylaldehyde with the free amino group, are valuable as antibacterial agents and are particularly valuable as therapeutic agents in poultry and animals, including man, in the treatment of infectious diseases caused by many Gram-positive and Gram-negative bacteria.
Type:
Grant
Filed:
October 31, 1973
Date of Patent:
March 23, 1976
Assignee:
Bristol-Myers Company
Inventors:
Takayuki Naito, Jun Okumura, Hajime Kamachi